Purpose, strategy and culture

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and COPD. Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation treatments that work in distinct ways to help as many people as possible. ​

​We’re building on our decades of knowledge in inflammatory mechanisms to target fibrotic lung, liver and kidney disease.

Our ambition is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and gynaecologic cancers into lung and gastrointestinal cancers, as well as other solid tumours. ​

​Our research uses precision medicine-based technology to match the right treatment to the right patient.

For nearly four decades, we’ve worked to improve the lives of people living with HIV or those who could benefit from prevention and protection from injection.

​Our work in HIV is led by ViiV Healthcare, which we majority-own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV with an ambition to end the HIV epidemic.

We intend to have a positive impact on the lives of more than 2.5 billion people by the end of the decade and a significant proportion of this will be through our work in infectious diseases. Our portfolio here is the broadest in the industry. 

Our priorities include seasonal infections, chronic infections, common childhood diseases and rarer but critical conditions like meningitis. We also focus on bacterial infections where resistance is creating an urgent need for new treatments.